Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

DARK SECRETS: Arcturus therapeutics s return on capital employed overview - The Real Truth

Benzinga Pro data, Arcturus Therapeutics (NASDAQ:ARCT) reported Q1 sales of $5.24 million. Earnings fell to a loss of $51.17 million, resulting in a 32.35% decrease from last quarter. Arcturus Therapeutics collected $5.79 million in revenue during Q4, but reported earnings showed a $38.66 million loss.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.